M200 2009.

Methods	Multicentre open‐label RCT; enrolment in USA from July 2007 to Oct 2008. (ID: NCT00635193)
Participants	127 women with stage III/IV PS or PR ROC. Maximum of 2 prior chemotherapy treatments (at least one of which was platinum/taxane based); at least one measurable lesion to assess response by RECIST.
Interventions	Volociximab (M200) is an anti‐angiogenic integrin inhibitor/monoclonal antibody. Two dosage regimes were tested combined with PLD versus PLD alone: Arm 1: PLD 40 mg/m² q4wk (66 women) Arm 2: M200 15 mg/kg qwk + PLD 40 mg/m² q4wk (34 women) Arm 3: M200 15 mg/kg q2wk + PLD 40 mg/m² q4wk (27 women)
Outcomes	Efficacy, safety and tolerability
Notes	No useable data. Results were reported as follows: 'The most common Grade 3 to 4 AEs (≥5% in any group) were abdominal pain, intestinal obstruction, ascites, fatigue, hypoalbuminemia, and cytopenias. The incidence of AEs was balanced across treatment groups. "There were no CRs; PRs were 16%, 18%, and 19%....Preliminary analysis of PFS suggested that there was a low probability of detecting a statistically significant difference in favor of V+PLD, so the study was closed to enrollment."
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not described.
Allocation concealment (selection bias)	Unclear risk	Not described.
Blinding of participants and personnel (performance bias) All outcomes	High risk	Open‐label study.
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not described.
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Efficacy and safety were not clearly detailed in the ASCO 2009 abstract which is the only publication for this study.
Selective reporting (reporting bias)	Unclear risk	Baseline data were not reported.
Other bias	Unclear risk	Limited information was available and results have not been published in full. Dr Obrocea of Abbott Laboratories was emailed on 28/11/2012 for final study data.